Table 1.

Demographic and clinical characteristics of the cohort

	Healthy control subjects		Patients with iRBD		Patients with Parkinson’s disease
	Visit 1	Visit 2	Visit 1	Visit 2	Visit 1	Visit 2
n	55	28	43	21	135	83
Age, years	62.0 ± 9.2	62.3 ± 8.9	67.6 ± 5.1*	69.2 ± 5.3	61.6 ± 9.4#	63.9 ± 9.1
Sex, male/female	30/25	9/19	38/5*	17/4	85/50#	52/31
Time from visit 1, years	n/a	2.0 ± 0.1	n/a	2.1 ± 0.2	n/a	1.9 ± 0.4
Disease duration, years	n/a	n/a	n/a	1.1 ± 0.5 (4 iRBD)	1.5 ± 1.1	3.7 ± 1.1
Hoehn and Yahr stage	0.1 ± 0.5	0.1 ± 0.4	0.7 ± 1.0*	1.2 ± 0.9	2.0 ± 0.2 *,#	2.0 ± 0.2
LEDD, mg	n/a	n/a	n/a	210.5 ± 181.7 (4 iRBD)	350.6 ± 252.6 (121 PD)	490.8 ± 267.5 (77 PD)
MDS-UPDRS III OFF	5.5 ± 5.2	6.8 ± 5.4	11.5 ± 6.3*	19.0 ± 8.3	30.3 ± 7.8 *,#	33.9 ± 7.8
MoCA	28.0 ± 1.7	28.6 ± 1.8	27.3 ± 2.3	26.7 ± 3.2	27.4 ± 2.2	27.2 ± 3.6
Mattis DRS	139.6 ± 3.9	141.3 ± 3.0	137.3 ± 6.2*	139.5 ± 4.5	138.9 ± 4.4	136.7 ± 15.8
ASBPD hypodopaminergic	0.8 ± 1.0	0.7 ± 1.2	1.7 ± 2.5	2.4 ± 3.1	2.0 ± 1.9*	2.1 ± 1.9
ASBPD hyperdopaminergic	0.1 ± 0.4	0.2 ± 0.5	0.3 ± 0.7	0.4 ± 1.0	1.1 ± 1.5*,#	1.3 ± 1.8
Laterality of first motor symptoms in the body, right/left	n/a	n/a	n/a	n/a	78/57	46/37
DaTScanTM delay relative to MRI, years	0.2 ± 0.2	0.2 ± 0.3	0.3 ± 0.2	0.1 ± 0.1	0.2 ± 0.2	0.1 ± 0.2

Values are presented as mean ± SD. ASBPD = Ardouin’s Scale Of Behaviour In Parkinson’s Disease; LEDD = levodopa equivalent daily dose; Mattis DRS = Mattis dementia rating scale; MoCA = Montréal Cognitive Assessment Score; n/a = not available.

^* P < 0.05 denote significant differences between patients with Parkinson’s disease (PD) or patients with iRBD and healthy control subjects at visit 1.

^# P < 0.05 denote significant differences between patients with Parkinson’s disease and patients with iRBD and healthy control subjects at visit 1.